Medicine and Dentistry
Acute Graft Versus Host Disease
10%
Adverse Event
13%
Biopsy Technique
20%
Bovine Serum Albumin
10%
Cell Transplantation
11%
Chlormethine
10%
Chronic Inflammation
10%
Clinical Research
10%
Cutaneous Lymphoma
10%
Cutaneous T Cell Lymphoma
79%
Dermatological Agent
26%
Dermatology
38%
Diagnosis
21%
Diseases
38%
Drug Eruption
10%
Exanthem
11%
Generalized Pustular Psoriasis
10%
Graft Versus Host Reaction
26%
Hematopoietic Cell
25%
Histopathology
13%
Hypericin
10%
Immunity
12%
Kidney Pancreas Transplantation
10%
Larynx
10%
Lung Transplantation
10%
Lupus Erythematosus Panniculitis
10%
Lymphoma Diagnostics
10%
Malignant Neoplasm
20%
Melanocytic Proliferation
10%
Metastatic Carcinoma
10%
Mogamulizumab
30%
Mycosis fungoides
62%
Neoplasm
17%
Ponatinib
10%
Post-Hoc Analysis
10%
Prevalence
10%
Propylthiouracil
10%
Protein Tyrosine Kinase
10%
Quality of Life
32%
Retrospective Study
20%
Sodium Bicarbonate
10%
Stevens-Johnson Syndrome
20%
Superagonist
10%
T Cell
12%
Telomerase Reverse Transcriptase
10%
Toxic Epidermal Necrolysis
20%
Transplantation
33%
Tyrosine-Kinase Inhibitor
10%
Vascular Endothelium
10%
Vorinostat
18%
Keyphrases
Adult Patients
11%
Adverse Events
14%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
13%
ANCA-associated Vasculitis
10%
Assessment of Quality of Life
12%
Atypical Melanocytic Proliferation
10%
CD30+
11%
Chlormethine
20%
Chronic Inflammation
10%
Clinical Dermatology
10%
Clinical Diagnosis
13%
Clinical Research
10%
Clinical Severity
10%
Cutaneous Drug Eruption
10%
Cutaneous Lymphoma
10%
Cutaneous T-cell Lymphoma
100%
Enzastaurin
10%
First-in-human
10%
Graft-versus-host Disease (GvHD)
36%
Granulomatous Inflammation
10%
Health-related Quality of Life
15%
Histone Deacetylase Inhibitor (HDACi)
10%
Histopathological Features
12%
Immune Checkpoint Inhibitors
10%
Immunophenotypic Profile
10%
Inhibitor Resistance
10%
Inpatient Dermatology
10%
Lymphoma Diagnostics
10%
Lymphoproliferative Disorders
10%
MAVORIC
20%
Mechlorethamine Gel
20%
Metastasis
10%
Migration Routes
10%
Mogamulizumab
30%
Mycosis Fungoides
83%
Pathological Findings
12%
Phase II Trial
20%
Primary Cutaneous T-cell Lymphoma
11%
Pruritus
12%
Quality of Life
16%
Real-world Experience
20%
Relapsed or Refractory
15%
Risk Prediction Model
10%
Specific Instrument
10%
Stevens-Johnson Syndrome/toxic Epidermal Necrolysis
20%
Superagonist
10%
Tissue Culture
10%
Transplantation
11%
United States
12%
Vorinostat
18%
